Like TFs, many oncogenic drivers in cancer are of undruggable nature, such as the small GTPases KRAS and HRAS. Therefore, the ability to program a heritable targeted silencing state in such major oncogenic drivers would be a high impact accomplishment with far reaching clinical implications for cancer treatment. Here, KRAS is linked to cancer.